Skip to main content

Table 2 Clinical and parasitological response rates for artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) using per protocol analysis, western Kenya 2011

From: A randomized trial of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated malaria among children in western Kenya

Outcome AL DP p-value
  % (95% CI) % (95% CI)  
Early treatment failure 0% (0%–3%) (0/137) 0% (0%–3%) (0/137) 1
Day 3 parasite clearance 99% (96%–99%) (130/131) 100% (97%–100%) (126/126) 0.34
Day 28 PCR-uncorrected ACPR * 61% (52%–70%) (71/116) 83% (75%–89%) (96/116) 0.001
Day 28 PCR-corrected ACPR ** 97% (92%–99%) (105/108) 99% (95%–100%) (114/115) 0.48
Day 42 PCR-uncorrected ACPR 44% (35%–54%) (49/111) 54% (45%–63%) (61/113) 0.14
Day 42 PCR-corrected ACPR 96% (90%–99%) (97/101) 96% (91%–99%) (105/109) 0.26
  1. *Polymerase chain reaction-uncorrected adequate clinical and parasitological response.
  2. **Polymerase chain reaction-corrected adequate clinical and parasitological response.